Alcon stock: Q3 growth holds as 2026 outlook narrows

Alcon reported its third-quarter 2026 results on Tuesday, November 10, highlighting continued growth in eye care while narrowing parts of its full-year outlook. The company's November 10 release covered the three months ended September 30.

Sales reached 2.717 billion US dollars, up 5 percent from the year-earlier quarter. Diluted earnings per share rose 13 percent to 0.54 US dollars, while core diluted earnings per share, a non-IFRS measure, increased 15 percent to 0.91 US dollars.

Growth Meets Tighter Profit Targets

Vision Care sales increased 6 percent, supported by ocular health and contact lenses. Surgical sales grew 4 percent, with equipment and other revenue up 11 percent and consumables up 6 percent. Implantables declined 2 percent as competitive pressure affected the U.S. market, although PanOptix Pro and international markets provided support.

Alcon kept its 2026 constant-currency sales-growth objective at approximately 6 percent, the midpoint of its earlier range. It narrowed expected core operating-margin expansion to 100 to 150 basis points from 90 to 190 basis points and reduced its core diluted EPS growth range to 12 to 14 percent from 12 to 15 percent.

The release also pointed to one-off factors in the period. Third-quarter operating income benefited from a 58 million US dollar tariff refund, while first-nine-month reported earnings reflected a 402 million US dollar pre-tax non-cash charge linked to discontinuing the PowerVision programs. Core figures exclude selected items including amortization, acquisition-related costs and efficiency measures.

Alcon stock traded at 67.04 euros on Lang & Schwarz at 11:33 CET on Saturday, November 14.

Broader market sentiment and healthcare-sector trading remain relevant as investors assess Alcon's updated earnings path; see Current market reports.

Find More news and analyses on Alcon stock.